Your session is about to expire
← Back to Search
Maplirpacept + PLD for Ovarian Cancer
Study Summary
This trial is testing a new cancer drug, TTI-622, in combination with an existing cancer drug, Pegylated liposomal doxorubicin. The trial will enroll approximately 50 patients in two phases to test different doses of the new drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My ovarian tumor is low-grade or borderline.I have had 4 or fewer treatments for my platinum-resistant condition.You have had serious allergic reactions to antibodies in the past.I have a history of significant bleeding disorders or episodes.My cancer returned within 6 months after platinum treatment or I can't receive/declined further platinum therapy.My side effects from previous treatments are mild, except for hair loss or stable nerve pain.My organs and blood cells are working well.I have previously been treated with anti-CD47 or anti-SIRPα therapy.My cancer is confirmed to be ovarian, fallopian tube, or peritoneal.I have had a heart attack or other heart-related emergency.I have had brain metastases or carcinomatous meningitis.I have a history of serious heart failure.You have a tumor that can be measured using specific guidelines.I am fully active or can carry out light work.I have been diagnosed with ovarian, fallopian tube, or peritoneal cancer.My cancer has worsened despite standard treatments, or I cannot tolerate them.I have an autoimmune disease treated with specific drugs.My condition worsened within 3 months after finishing my first platinum-based treatment.I have had an organ or stem cell transplant.My cancer is not of the common 'epithelial' type; it could be a mixed Mullerian tumor.I am currently on systemic steroid therapy.My cancer got worse 1 to 6 months after my last platinum-based treatment.
- Group 1: Phase 1: Dose Escalation
- Group 2: Phase 2: Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the overarching ambitions of this research endeavor?
"This medical trial will assess the efficacy of TTI-622 MTD or RP2D when combined with PLD over the course of 3 years. The primary outcome is to measure clinical activity, while secondary outcomes include duration of progression-free survival (PFS), time to progression and new metastases, and overall survival from study treatment initiation until death from any cause."
Are researchers actively enrolling participants in this investigation?
"According to clinicaltrials.gov this current medical trial, which was first made available on August 1st 2022, is searching for participants and has recently been updated as of the 24th October 20202."
Could you provide insight into the potential health risks of Pegylated Liposomal Doxorubicin?
"With Phase 2 clinical data indicating a certain degree of safety, our team at Power gave Pegylated Liposomal Doxorubicin a score of two on the risk scale."
To what extent are hospitals administering this experiment?
"Recruitment for this trial is currently underway at 14 different medical sites, such as the Cleveland Clinic Fairview Hospital in Cleveland, UPMC Hillman Cancer Center-Investigational Drug Services in Pittsburgh, and Oklahoma Cancer Specialist and Research Institute LLC in Tulsa."
What is the uppermost limit of individuals engaging in this clinical experiment?
"Correct. Clinicaltrials.gov's records demonstrate that this research, first posted on August 1st 2022, is in search of participants. This project demands 50 volunteers from 14 different medical sites."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
What state do they live in?
What site did they apply to?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger